Hostile Takeover | Fox Lake Towing and Recovery

Tag: Hostile Takeover

Sanofi-Aventis, Genzyme Are on the Brink of a Merger

by Melly Alazraki on Feb.07, 2011, under Towing

It seems that months of merger talks between French pharma Sanofi-Aventis and U.S. biotech Genzyme have entered the home stretch. This week, Sanofi is expected to offer $74 a share for Genzyme, with an option included potentially worth $5 to $6 a share.

Continue reading Sanofi-Aventis, Genzyme Are on the Brink of a Merger

Sanofi-Aventis, Genzyme Are on the Brink of a Merger originally appeared on DailyFinance on Mon, 07 Feb 2011 10:40:00.

Filed Under: Company News, Health Care, Genzyme Corporation , Sanofi Aventis, Stocks in the News

Leave a Comment :biologic, campath, Company News, contingent value right, CVR, drugs, generic drugs, GENZ, Genzyme Corporation, Health Care, Hostile Takeover, Lemtrada, merger, mergers and acquisitions, multiple sclerosis, multiple sclerosis drugs, patent cliff, patents, pharmaceutical stocks, pharmaceuticals, Sanofi Genzyme offer, sanofi-aventis, SNY, SNY, GENZ, Stocks in the News more...

Genzyme Tries to Convince Sanofi-Aventis Its MS Drug Is Worth More

by Melly Alazraki on Dec.20, 2010, under Towing

The U.S. biotech is holding an analyst and investor meeting focused on the commercial potential of its multiple sclerosis drug Campath. The goal: to convince Paris-based Sanofi-Aventis to raise its hostile takeover offer in a battle that has now gone on for five months.

Continue reading Genzyme Tries to Convince Sanofi-Aventis Its MS Drug Is Worth More

Genzyme Tries to Convince Sanofi-Aventis Its MS Drug Is Worth More originally appeared on DailyFinance on Mon, 20 Dec 2010 10:50:00.

Filed Under: Company News, Genzyme Corporation , Sanofi Aventis, Stocks in the News

Leave a Comment :@aoloriginal, alemtuzumab, bid, biotech, biotech stocks, biotechnology, campath, cancer, Company News, contingent value rights, GENZ, GENZ, SNY, genzyme, Genzyme Corporation, Hostile Takeover, mergers and acquisitions, pharmaceuticals, price per share, sanofi-aventis, SNY, Stocks in the News, Takeover more...

Sanofi Denies Offering $69-$80 Price Range to Genzyme

by Melly Alazraki on Oct.08, 2010, under Towing

There’s a new plot twist in the takeover battle between French pharmaceutical giant Sanofi-Aventis and U.S. drugmaker Genzyme. A regulatory filing made by Genzyme on Thursday claims Sanofi may be willing to go much higher than its current $69 bid — a claim the French company disputes.

Continue reading Sanofi Denies Offering $69-$80 Price Range to Genzyme

Sanofi Denies Offering $69-$80 Price Range to Genzyme originally appeared on DailyFinance on Fri, 08 Oct 2010 08:30:00.

Filed Under: Company News, Health Care, Genzyme Corporation , Johnson & Johnson, Pfizer, Sanofi Aventis, Stocks in the News

Leave a Comment :biotech, biotech stocks, biotechnology stocks, Company News, GENZ, genzyme, Genzyme Corporation, genzyme price range, genzyme rejects sanofis bid, Genzyme takeover, Health Care, hostile bid, Hostile Takeover, JNJ, Johnson & Johnson, mergers and acquisitions, patent cliff, pfe, Pfizer, pharmaceutical industry, pharmaceutical stocks, pharmaceuticals, Sanofi Genzyme offer, sanofi-aventis, Sanofi-Aventis takeover genzyme, SNY, SNY, GENZ, PFE, JNJ, Stocks in the News more...

Sanofi-Aventis Launches Hostile Bid for Genzyme

by Melly Alazraki on Oct.04, 2010, under Towing

After months of courting U.S. drugmaker Genzyme, French pharmaceutical company Sanofi-Aventis launched a hostile bid valued at approximately $18.5 billion, or $69 a share, for all outstanding shares of Genzyme common stock.

Continue reading Sanofi-Aventis Launches Hostile Bid for Genzyme

Sanofi-Aventis Launches Hostile Bid for Genzyme originally appeared on DailyFinance on Mon, 04 Oct 2010 06:55:00.

Filed Under: Genzyme Corporation , Sanofi Aventis, Stocks in the News